AR037951A1 - Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada - Google Patents

Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada

Info

Publication number
AR037951A1
AR037951A1 ARP020105039A ARP020105039A AR037951A1 AR 037951 A1 AR037951 A1 AR 037951A1 AR P020105039 A ARP020105039 A AR P020105039A AR P020105039 A ARP020105039 A AR P020105039A AR 037951 A1 AR037951 A1 AR 037951A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
orxally
active
taxane derivative
biodisponibility
Prior art date
Application number
ARP020105039A
Other languages
English (en)
Inventor
Joseph Ballard Bogardus
Robert Kevin Perrone
Sailesh A Varia
Krishnaswamy S Raghavan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR037951A1 publication Critical patent/AR037951A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que comprenden un derivado de taxano oralmente activo y un agente de solubilización farmacéuticamente aceptable, y que proporciona absorción oral efectiva y consistente del derivado de taxano. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende un derivado de taxano oralmente activo que tiene las fórmulas (1) y (2), en donde: R es fenilo, isopropilo, o ter-butilo; R1 es -C(O)Rz en la cual Rz es (CH3)3CO-, (CH3)3CCH2-, CH3(CH2)3O-, ciclobutilo-, ciclohexiloxi, o (2-furilo); y R2 es CH3C(O)O-, y un agente de solubilización farmacéuticamente aceptable para dicho derivado de taxano.
ARP020105039A 2001-12-20 2002-12-19 Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada AR037951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34288901P 2001-12-20 2001-12-20

Publications (1)

Publication Number Publication Date
AR037951A1 true AR037951A1 (es) 2004-12-22

Family

ID=23343716

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020105039A AR037951A1 (es) 2001-12-20 2002-12-19 Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada

Country Status (24)

Country Link
US (1) US20030220391A1 (es)
EP (1) EP1465618A2 (es)
JP (1) JP2006501134A (es)
KR (1) KR20040066921A (es)
CN (1) CN1273130C (es)
AR (1) AR037951A1 (es)
AU (1) AU2002361701A1 (es)
BR (1) BR0215184A (es)
CA (1) CA2470826A1 (es)
GE (1) GEP20063806B (es)
HR (1) HRP20040545A2 (es)
HU (1) HUP0500843A2 (es)
IL (1) IL162118A0 (es)
IS (1) IS7306A (es)
MX (1) MXPA04005877A (es)
NO (1) NO20043101L (es)
PE (1) PE20030742A1 (es)
PL (1) PL374283A1 (es)
RS (1) RS52904A (es)
RU (1) RU2004119557A (es)
TW (1) TW200302086A (es)
UY (1) UY27598A1 (es)
WO (1) WO2003053350A2 (es)
ZA (1) ZA200404584B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070280A2 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
WO2005030150A2 (en) 2003-09-25 2005-04-07 Tapestry Pharmaceuticals, Inc. 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US20060116420A1 (en) * 2004-11-23 2006-06-01 Ramakrishnan Chidambaram Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel
CN104667355A (zh) * 2005-02-18 2015-06-03 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
AU2012202903B2 (en) * 2005-02-18 2014-12-11 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
EP2233156B1 (en) 2005-07-15 2013-05-01 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
TWI429452B (zh) 2005-08-31 2014-03-11 Abraxis Bioscience Llc 包含弱水溶性藥劑及抗微生物劑之組合物
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
AU2008291930B2 (en) * 2007-08-24 2014-04-17 Slotervaart Participaties Bv Compositions for the treatment of neoplastic diseases
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
BRPI0820198A2 (pt) * 2007-11-12 2019-09-24 Novartis Ag composições farmacêuticas
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
KR101782306B1 (ko) 2009-11-25 2017-09-27 베링거 인겔하임 인터내셔날 게엠베하 분무기
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
ES2954961T3 (es) 2014-05-07 2023-11-27 Boehringer Ingelheim Int Unidad, nebulizador y método
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
KR102443739B1 (ko) 2014-05-07 2022-09-19 베링거 인겔하임 인터내셔날 게엠베하 분무기 및 컨테이너
CN103980232A (zh) * 2014-06-05 2014-08-13 北京诺普德医药科技有限公司 10-乙酰基多西紫杉醇及其用途
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN108066335B (zh) * 2016-11-11 2020-02-21 北京康辰药业股份有限公司 一种含有紫杉醇或其类似物的药物组合物及其制备方法
FR3113238B1 (fr) 2020-08-05 2024-04-05 Gattefosse Sas Utilisation comme excipient, d’un melange de macrogolglyceride laurique et de polyethylene glycol

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
ES2119996T3 (es) * 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PT932399E (pt) * 1996-03-12 2006-05-31 Pg Txl Co Lp Pro-farmacos de paclitaxel hidrossoluveis
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
EP1067923A4 (en) * 1997-12-31 2002-11-13 Bristol Myers Squibb Co 2-AROYL-4-ACYL PACLITAXEL (TAXEL) ANALOGS
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
JP2002544269A (ja) * 1999-05-17 2002-12-24 ブリストル−マイヤーズ スクイブ カンパニー パクリタキセルおよびパクリタキセル類似体の製造におけるシリルエーテルの切断のための新規反応条件
IL147851A0 (en) * 1999-07-16 2002-08-14 Bristol Myers Squibb Co Process for the preparation of a c-4 methylcarbonate analog of paclitaxel
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
US6750246B1 (en) * 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Also Published As

Publication number Publication date
WO2003053350A2 (en) 2003-07-03
IS7306A (is) 2004-06-10
RS52904A (en) 2006-12-15
EP1465618A2 (en) 2004-10-13
CA2470826A1 (en) 2003-07-03
CN1273130C (zh) 2006-09-06
CN1606437A (zh) 2005-04-13
ZA200404584B (en) 2005-09-13
WO2003053350A3 (en) 2004-01-15
BR0215184A (pt) 2006-06-06
PL374283A1 (en) 2005-10-03
GEP20063806B (en) 2006-04-25
JP2006501134A (ja) 2006-01-12
HRP20040545A2 (en) 2005-08-31
AU2002361701A1 (en) 2003-07-09
RU2004119557A (ru) 2005-04-20
IL162118A0 (en) 2005-11-20
US20030220391A1 (en) 2003-11-27
KR20040066921A (ko) 2004-07-27
TW200302086A (en) 2003-08-01
UY27598A1 (es) 2003-07-31
MXPA04005877A (es) 2004-09-13
HUP0500843A2 (hu) 2005-12-28
NO20043101L (no) 2004-07-19
PE20030742A1 (es) 2003-09-02

Similar Documents

Publication Publication Date Title
AR037951A1 (es) Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
DE60114994D1 (de) Blutplättchen-adp-rezeptor-inhibitoren
PT1447399E (pt) Derivado de 2-oxo-1-pirrolidina e as suas utilizacoes farmaceuticas
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
NO20073764L (no) Sammensetninger for behandling av HCV
EA200201262A1 (ru) Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
AR040553A1 (es) Combinacion que comprende un inhibidor de ibat y tratamiento terapeutico
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
AR034343A1 (es) Combinaciones farmaceuticas
DK1251846T3 (da) C4-Carbonattaxaner
UY27979A1 (es) Indoles sustituidos en posición 2,4
DE60120427D1 (de) Radicicol und monocillin und ihre analogen und ihre anwendungen
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
CO5590911A2 (es) Composiciones farmaceuticas a base de derivados de azetidina
ECSP034561A (es) Derivados puente de piperazina
SE0003476D0 (sv) Compounds
AR035110A1 (es) Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
MEP16408A (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
SE0000303D0 (sv) Novel compounds
BR0315016A (pt) Composição fumìgena
NO20014760D0 (no) C(10)-karbamoyloksysubstituerte taksaner som antitumormidler

Legal Events

Date Code Title Description
FB Suspension of granting procedure